The holy grail: pan-cancer-targeting T cells

Crowther and Dolton et al. identified an unconventional human T cell clone capable of killing many different types of cancer in vitro in an HLA-independent fashion while sparing healthy cells. Using genome-wide CRISPR-Cas9 screening, the researchers showed that the T cell clone recognized the ubiquitously expressed, mostly monomorphic, MHC-I-related protein MR1 on the surface of cancer cells when MR1 was loaded with a yet unidentified cancer-specific or cancer-associated ligand. Adoptive transfer of this T cell clone into immunodeficient NSG mice with leukemia reduced tumor burden and increased survival.

Cell membrane-based biomimetic technology for cancer phototherapy

How does the Galleri Test work?

Is Immunotherapy the Holy Grail for Pancreatic Cancer? - Pereira Lab

ars.els-cdn.com/content/image/1-s2.0-S000629522400

Targeting cancer with mRNA–lipid nanoparticles: key considerations

Frontiers Progress Toward Identifying Exact Proxies for

Dr Ying-Xian Pan - The Holy Grail of Safer Opioids: Targeting Mu

CIMT Annual Meeting 2022

Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer

Novel strategies for cancer immunotherapy: counter-immunoediting

Relevance of immune cell and tumor microenvironment imaging in the

CIMT Annual Meeting 2022